Hydromer, a company dealing in the manufacture and commercialization of specialized polymer and hydrogel products, has signed a supply and support contract with N8 Medical, an emerging biomedical technology firm, to develop and commercialize a new class of antimicrobial coatings for medical applications.
The collaboration will integrate N8 Medical's innovative range of synthetic antimicrobial compounds called Ceragenins (CSAs) with Hydromer's medical-grade polymeric coating technology expertise. CSAs are licensed from Brigham Young University and they mimic a wide range of activities of a critical part of the human immune system. The compounds are targeted to fight hospital-acquired infections (HAIs).
Tests have shown that coating methods, which integrate Ceragenins with Hydromer’s coating technology, are highly effective in fighting a broad range of microbes and biofilms. Thus, the methods have the potential to considerably decrease HAIs and save patients' lives by minimizing morbidity and securing healthcare systems globally. CSA-13, a Ceragenin compound, possesses effective antimicrobial properties and it acts as virucidal, bactericidal and fungicidal against several pathogens, including multidrug resistant strains of Pseudomonas aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA). In addition, the compound has the ability to prevent and eliminate fungal and bacterial biofilms.
David J. Richards, CEO of N8 Medical, stated that the combination of their technologies has potential in the antimicrobial medical coatings field and also has the capability to achieve significant savings for healthcare systems.
Source: http://www.hydromer.com/
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.